| Execution period | FY 2026-27 to FY 2030-31, five consecutive financial years, subject to shareholder approval |
|---|
NSE filing, NSE: SMT. Summary written from the filing by ALFA Finder's alert engine.
Sahajanand Medical Technologies Ltd: key numbers
- Share price
- ₹487.75
- Market cap
- ₹4,958 Cr
- Revenue (annual)
- ₹1,210 Cr
- Net profit (annual)
- ₹65.28 Cr
- Promoter holding
- 36.20%
- FII holding
- 35.09%Current quarter
Reference market data from a third-party provider, updated daily. Not a valuation or a recommendation.
More from Sahajanand Medical Technologies Ltd
All →Sahajanand Medical Technologies Earnings Call Transcript: Key Takeaways
Record Q2 FY27: revenue up 24.7% to about ₹373 Cr, EBITDA up 36.6%, margin 17.6%. Reported H1 PAT up only 7.5% due to a prior-year one-off tax credit; ex-it about 39%. Gross margin fell 170 bps on traded-product mix.
Sahajanand Medical Technologies Acquisition Worth ₹7.33 Cr
Sahajanand Medical's Irish subsidiary approved up to USD 7,80,000 investment in SNP Medical Corp. This lifts its stake to 17.19%, a related-party deal at arm's length.
- Value
- ₹7.33 Cr
- Execution
- Tentatively completed by 31 March 2027
Sahajanand Medical Technologies Investor Presentation: Key Takeaways
Q2 FY27 record: revenue ₹3,734mn (+24.7%), EBITDA ₹656mn (17.6% margin), PAT ₹265mn (+26.6%). H1 revenue ₹7,251mn (+24.9%). Growth led by Other and Shockwave-type SH products.
Sahajanand Medical Technologies Q2 FY27 Results: Net Profit ₹26.5 Cr, Up 26.8% YoY
Sahajanand Medical Technologies Ltd reported revenue from operations of ₹373.4 Cr (+24.7% YoY) and net profit of ₹26.5 Cr (+26.8% YoY) for Q2 FY27.
- Key figure
- Net profit ₹26.5 Cr · +26.8% YoY
Sahajanand Medical Technologies Legal & Regulatory
Sahajanand Medical Technologies received a GST DRC-01D recovery notice from Jharkhand tax authorities. The demand totals Rs. 34.29 lakh, which the company is contesting before appellate authorities.
- Value
- ₹0.34 Cr
Sahajanand Medical Technologies Credit Rating
CRISIL has upgraded Sahajanand Medical Technologies' long-term bank facility rating to CRISIL A-/Stable from BBB+/Stable. The upgrade reflects improved business risk, growing scale, and sustained profitability across its global stent manufacturing operations.
- Value
- ₹300.0 Cr
Other board meeting outcome announcements
All →CMX Holdings Board Meeting Outcome
Riwind Green Energy (formerly CMX Holdings) board approved altering its MOA main objects into six consolidated objects and a postal ballot notice. The change refocuses the company on solar, EPC, battery storage and renewable data-centre businesses.
Gretex Corporate Services Board Meeting Outcome
Gretex Corporate Services re-appointed Arvind Harlalka, Alok Harlalka and Rajiv Kumar Agarwal as directors after a board meeting. Terms are 60 months, effective from April 2027 and May 2027.
- Execution
- 60 months
Rajasthan Cylinders & Containers Board Meeting Outcome
Rajasthan Cylinders' board approved unaudited results for the quarter and half year ended September 30, 2026. The filing contains no financial figures.
Panasonic Carbon India Co Board Meeting Outcome
Panasonic Carbon's board recommended Brahmayya & Co. as statutory auditors for five years, from the 45th AGM in 2027. Standalone unaudited Q2 results were also approved.
- Execution
- Five years, from the conclusion of the 45th AGM (2027) to the conclusion of the 50th AGM (2032)
Safari Industries (India) Board Meeting Outcome
Safari Industries (India) Limited has approved a revised Code of Practices and Procedures for Fair Disclosure of Unpublished Price Sensitive Information. The amendment ensures compliance with SEBI Regulations.
B N Rathi Securities Board Meeting Outcome
B.N. Rathi Securities Limited appointed M/s. Vinay Surana & Co. as Internal Auditors for financial year 2026-27. This replaces M/s Penmetsa & Associates following their tenure completion.
- Execution
- Financial Year 2026-27